GS-441524: Difference between revisions

GS-441524
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Latest revision as of 12:08, 15 February 2025

GS-441524 is a nucleoside analog antiviral drug that has been studied for its potential use in treating viral infections, particularly those caused by coronaviruses. It is a prodrug of remdesivir, which is an antiviral medication used to treat COVID-19.

Chemical structure and properties[edit]

GS-441524 is a nucleoside analog, meaning it mimics the structure of natural nucleosides, which are the building blocks of nucleic acids like RNA and DNA. The chemical structure of GS-441524 allows it to interfere with the replication of viral RNA, thereby inhibiting the proliferation of the virus within the host organism.

Mechanism of action[edit]

GS-441524 works by incorporating itself into the viral RNA chain during replication. This incorporation leads to premature termination of the RNA chain, effectively halting the replication process of the virus. This mechanism is similar to that of other nucleoside analogs, which are commonly used in antiviral therapies.

Clinical applications[edit]

While GS-441524 itself is not approved for human use, its prodrug, remdesivir, has been authorized for emergency use in the treatment of COVID-19. GS-441524 has been studied in various animal models and has shown promise in treating infections caused by feline coronavirus, which can lead to feline infectious peritonitis (FIP), a fatal disease in cats.

Research and development[edit]

Research into GS-441524 has primarily focused on its efficacy and safety in treating viral infections. Studies have demonstrated its potential in inhibiting the replication of various coronaviruses, including those responsible for SARS and MERS. Ongoing research aims to further understand its pharmacokinetics and potential applications in human medicine.

Related pages[edit]

@@ Line 1: / Line 1: @@
-'''GS-441524''' is an [[antiviral drug]] that is structurally related to [[remdesivir]]. It is a [[nucleoside analogue]], which means it mimics the building blocks of [[RNA]] and [[DNA]]. When incorporated into the growing RNA chain of a [[virus]], it causes premature termination of [[transcription]], effectively stopping the virus from replicating.
+{{Short description|A nucleoside analog antiviral drug}}
+{{Drugbox
+| verifiedfields = changed
+| verifiedrevid = 477002123
+| image = GS-441524_skeletal.svg
+| image_size = 200px
+| image_alt = Skeletal structure of GS-441524
+}}
-==History==
+'''GS-441524''' is a nucleoside analog antiviral drug that has been studied for its potential use in treating viral infections, particularly those caused by [[coronavirus]]es. It is a prodrug of [[remdesivir]], which is an antiviral medication used to treat [[COVID-19]].
-GS-441524 was first synthesized by [[Gilead Sciences]], a biopharmaceutical company based in the United States. It was initially developed as a potential treatment for [[Ebola virus disease]], but it was later found to be effective against other viruses, including the [[coronavirus]] that causes [[Feline Infectious Peritonitis]] (FIP) in cats.
-==Mechanism of Action==
+==Chemical structure and properties==
-GS-441524 works by inhibiting the [[RNA-dependent RNA polymerase]] (RdRp), an enzyme that is crucial for the replication of RNA viruses. By incorporating itself into the growing RNA chain, GS-441524 causes premature termination of transcription, effectively stopping the virus from replicating.
+[[File:GS-441524_skeletal.svg|thumb|right|Skeletal structure of GS-441524]]
+GS-441524 is a nucleoside analog, meaning it mimics the structure of natural nucleosides, which are the building blocks of [[nucleic acids]] like [[RNA]] and [[DNA]]. The chemical structure of GS-441524 allows it to interfere with the replication of viral RNA, thereby inhibiting the proliferation of the virus within the host organism.
-==Clinical Use==
+==Mechanism of action==
-GS-441524 has been used experimentally to treat cats with FIP, a fatal and incurable disease caused by a coronavirus. It has also been proposed as a potential treatment for [[COVID-19]], the disease caused by the novel coronavirus SARS-CoV-2. However, as of now, it is not approved for use in humans.
+GS-441524 works by incorporating itself into the viral RNA chain during replication. This incorporation leads to premature termination of the RNA chain, effectively halting the replication process of the virus. This mechanism is similar to that of other nucleoside analogs, which are commonly used in antiviral therapies.
-==Safety and Side Effects==
+==Clinical applications==
-The safety and side effects of GS-441524 are not well-studied in humans. In cats, it has been reported to cause mild side effects such as loss of appetite and lethargy.
+While GS-441524 itself is not approved for human use, its prodrug, [[remdesivir]], has been authorized for emergency use in the treatment of COVID-19. GS-441524 has been studied in various animal models and has shown promise in treating infections caused by [[feline coronavirus]], which can lead to [[feline infectious peritonitis]] (FIP), a fatal disease in cats.
-==See Also==
+==Research and development==
+Research into GS-441524 has primarily focused on its efficacy and safety in treating viral infections. Studies have demonstrated its potential in inhibiting the replication of various coronaviruses, including those responsible for [[SARS]] and [[MERS]]. Ongoing research aims to further understand its pharmacokinetics and potential applications in human medicine.
+==Related pages==
 * [[Remdesivir]]
+* [[Nucleoside analog]]
 * [[Antiviral drug]]
-* [[Nucleoside analogue]]
+* [[Coronavirus]]
-* [[RNA-dependent RNA polymerase]]
 [[Category:Antiviral drugs]]
-[[Category:Nucleoside analogues]]
+[[Category:Nucleoside analogs]]
-[[Category:Experimental drugs]]
-{{medicine-stub}}